GlassScriptPhysician profile
Astrid J Serauto Canache
NPI 1619351996
$13,870.81
in general payments reported to CMS, 2019-2025
25 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $9,968 · 2023: $2,235 · 2024: $1,365 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,064 · Travel and Lodging: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,063.52 |
| Travel and Lodging | $727.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,561.94 | 2022 | |
| Biotronik INC. | $2,720.16 | 2021-2022 | |
| Medtronic, INC. | $2,597.11 | 2021-2024 | Micra, Mycarelink, Hawkone |
| Edwards Lifesciences Corporation | $1,815.27 | 2022 | |
| Abiomed | $617.82 | 2023-2024 | Impella |
| Boston Scientific Corporation | $567.82 | 2022-2024 | Synergy, Bodyguardian, Watchman Access System |
| Inari Medical, INC. | $350.59 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Irhythm Technologies, INC. | $237.96 | 2023-2024 | Zio Xt Patch, Zio Monitor, Zio At Patch |
| Novartis Pharmaceuticals Corporation | $210.06 | 2023-2025 | |
| Pfizer INC. | $193.45 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $183.44 | 2022-2024 | Farxiga |
| Amgen INC. | $175.95 | 2023-2025 | Repatha |
| Teleflex LLC | $136.12 | 2024 | Guideliner |
| Janssen Pharmaceuticals, INC | $101.86 | 2022 | |
| Cardiovascular Systems INC. | $83.20 | 2023 | Diamondback Coronary |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.60 | 2022-2025 | Verquvo, Capvaxive |
| Atricure, INC. | $47.06 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.32 | 2023-2024 | Lifevest |
| Baxter Healthcare | $40.75 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.30 | 2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $18.68 | 2025 | |
| Esperion Therapeutics, INC. | $18.33 | 2023 | Nexletol |
| Novo Nordisk INC | $18.03 | 2024 | |
| Thrombolex, INC. | $15.50 | 2023 | |
| G Medical Diagnostic Services, INC. | $14.49 | 2023 | Cardiac Monitoring Suite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Astrid Serauto Canache listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.